ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 53

Activation of the Desacetylase Sirtuin-1 Counteracts the Activated and Proangiogenic Profile of Endothelial Cells in Rheumatoid Arthritis and Alleviates Experimental Arthritis

Agathe Leblond 1, Sonia Pezet 1, Anne Cauvet 1, Claudine Casas 1, Julie Pires Da Silva 2, Roxane Herve 3, Luca Semerano 4, Christophe Lemaire 5, Yannick Allanore 6 and Jerome Avouac6, 1INSERM U1016, Paris, France, 2Paris Sud University, Chateany Malabry, France, 3Paris 13 University, Bobigny, France, 4INSERM UMR 1125 , Université Paris 13, Bobigny, France, 5Paris Sud University, Chatenay malabry, France, 6Paris Descartes University, Cochin Hospital, Rheumatology department, Paris, France

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Angiogenesis, endothelial cells and animal models, Rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 10, 2019

Title: RA – Etiology & Pathogenesis Poster I

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: To decipher the phenotype of endothelial cells (ECs) derived from circulating progenitors issued from patients with rheumatoid arthritis (RA).

Methods: Proliferation capacities between RA and control ECs was compared using the xCELLigence™ RTCA System. rh-TNFa-induced EC activation was analyzed by adhesion cell expression, VEGF synthesis and stress fiber formation. Angiogenic properties of ECs were assessed in vitroby tube formation on Matrigel and migration capacities through VEGF stimulation in modified Boyden chambers, and in vivoin a mouse model of tumoral neovascularization. Microarray experiments were then performed on Affymetrix GeneChip® Human Exon 1.0 ST Arrays in ECs issued from 18 RA patients and 11 age and sex-matched healthy controls. Expression of identified candidates was assessed by RT-PCR and western blots in ECs and by immunohistochemistry in the synovium. Their functional importance was then evaluated in vitroafter gene invalidation by siRNA and adenoviral gene overexpression, and in vivoin the mouse model of methyl-BSA-induced arthritis.

Results: RA ECs displayed higher proliferation rate, greater sensitization to TNF-α,with increased VEGF production, ICAM/VCAM expression, and more prominent stress fiber formation, as well as enhanced angiogenic capacities, characterized by accelerated tube formation and increased migration capacities through VEGF stimulation, compared co control ECs. The subcutaneous transplantation of murine colon carcinoma (CT-26) cells with RA ECs in CB17-SCID mice markedly amplified tumor growth and intra-tumoral neovessel density, compared to the transplantation of control ECs.

Supervised microarray analyses identified the NAD-dependent protein deacetylase sirtuin-1 (SIRT1) as a relevant gene candidate. A strikingly decreased SIRT1 gene / protein expression and enzyme activity was detected in RA ECs upon the regulation of miR217 and miR181. A markedly decreased SIRT1 expression was also observed in synovial vessels of RA patients.

Invalidation of SIRT1 with specific siRNA in control ECs was associated with a proliferative and activated profile upon TNFa stimulation, trough the acetylation of p53 and p65, and with the development of proangiogenic capacities through the upregulation of the matricellular protein CYR61. Conditional deletion of SIRT1 in ECs through a Cre-LoxP recombination system increased angiogenesis and worsened signs of arthritis in methyl-BSA-induced arthritis.Conversely, adenoviral overexpression of SIRT1 in RA ECs reversed the activated and proangiogenic phenotype of RA ECs, and activation of SIRT1 with resveratrol alleviated signs of experimental methyl-BSA-induced arthritis.

Conclusion: SIRT1 expression is reduced in synovial vessels of RA patients. SIRT1 invalidation in ECs reproduces the proliferative, activated and proangiogenic profile of RA ECs and exacerbate experimental arthritis. These effects were reversed by SIRT1 activation. These results support the implication of SIRT1 in RA synovial neoangiogenesis and may have direct therapeutic implications, since targeting angiogenesis, and especially SIRT1, might be used as a complementary therapeutic approach in RA.


Disclosure: A. Leblond, None; S. Pezet, None; A. Cauvet, None; C. Casas, None; J. Pires Da Silva, None; R. Herve, None; L. Semerano, None; C. Lemaire, None; Y. Allanore, None; J. Avouac, Pfizer, 2, 8.

To cite this abstract in AMA style:

Leblond A, Pezet S, Cauvet A, Casas C, Pires Da Silva J, Herve R, Semerano L, Lemaire C, Allanore Y, Avouac J. Activation of the Desacetylase Sirtuin-1 Counteracts the Activated and Proangiogenic Profile of Endothelial Cells in Rheumatoid Arthritis and Alleviates Experimental Arthritis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/activation-of-the-desacetylase-sirtuin-1-counteracts-the-activated-and-proangiogenic-profile-of-endothelial-cells-in-rheumatoid-arthritis-and-alleviates-experimental-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/activation-of-the-desacetylase-sirtuin-1-counteracts-the-activated-and-proangiogenic-profile-of-endothelial-cells-in-rheumatoid-arthritis-and-alleviates-experimental-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology